Racial Disparities in Prostate Ca Recurrence

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Black men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138).

SAN FRANCISCO—Black men are more likely than white men to have a prostate cancer recurrence after radical prostatectomy, Hadley M. Wood, MD, reported at the 2006 Prostate Cancer Symposium (abstract 138). Dr. Wood is a resident at the Glickman Urological Institute of the Cleveland Clinic Foundation. This prospective study assessed biochemical failure rates in 2,910 men of both races during two time periods: the "early PSA period" (1987-1997) and the "later PSA period" (1998-2004). The men were followed for at least 12 months after surgery, with biochemical failure defined as PSA more than 0.2 ng/mL. Both groups were more likely to have organ-confined disease during the later PSA period; rates increased from 54% in the early period to 76% in the later period for black men (P = .0001) and from 50% to 71% for white men (P < .0001). Progression-free survival (PFS) at 5 years increased in both groups between the two periods, from 67% to 71% for blacks and from 78% to 82% for whites. The difference in PFS between the races, however, remained constant at 11% during both periods. Dr. Wood said this difference occurred even though black men were more likely to have organ-confined disease, and both groups had similar Gleason scores, clinical T stage, and initial PSA level.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Related Content